FDA Approves Opzelura (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD)

By | September 23, 2021

[unable to retrieve full-text content]WILMINGTON, Del.–(BUSINESS WIRE) September 21, 2021 — Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream for the short-term and non-continuous chronic treatment of…
Drugs.com – New Drug Approvals

Read More:  FDA Approves Repatha (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia